European CLL Association (ECLLA)
Advancing care and research in Chronic Lymphocytic Leukemia
One Europe. Equal care.
📢 Featured News
📰 ECLLA Newsletter – October 2026 Edition Now Available
The European CLL Association (ECLLA) is pleased to announce the release of the October 2026 edition of the ECLLA Newsletter. In this edition, we share some exciting milestones as ECLLA continues to grow and strengthen its European network. You'll find highlights from...
📢 ECLLA Publishes European Policy Brief 2026 and Launches It at the European Parliament
The European CLL Association (ECLLA) has published its European Policy Brief 2026, setting out key priorities and recommendations to help address inequalities in chronic lymphocytic leukaemia (CLL) care across Europe. The Brief was formally launched on 30 September...
🎓 ECLLA CLUB: Join Our Second Educational Session “Immune Health in CLL” September, 29th – REGISTRATION OPEN
Dear ECLLA Members, We are pleased to invite you to our second ECLLA Club session: Immune Health in CLL. This interactive session will feature an expert-led presentation by Dr Lydia Scarfò, Assistant Professor of Internal Medicine & Consultant Haematologist,...
ABOUT ECLLA
The European CLL Association (ECLLA) works to improve equity, access and quality of care for people living with chronic lymphocytic leukemia (CLL) across Europe through advocacy, education, collaboration and policy engagement.
Mission
ECLLA unites clinicians, researchers, patient advocates, and industry partners to advance understanding of CLL.
Vision
Values
ECLLA’s actions and partnerships are guided by a shared ethical foundation, centered on respect and integrity in everything we do.
CORE FOCUS AREA
Policy & Access
ECLLA advocates for equitable access to innovative therapies and diagnostics across the EU. It participates in policy discussions to promote harmonised standards of care throughout Europe, ensuring that all patients benefit from advances in CLL treatment.
Partnership building & Collaboration
ECLLA brings together national CLL and blood cancer organisations, patient advocates, clinicians, researchers, and industry partners. By fostering networking and collaboration through forums and partnerships, ECLLA strengthens the CLL community across Europe and promotes the sharing of knowledge and best practice.
Patient Empowerment & Education
ECLLA is dedicated to developing accessible, multilingual educational materials that explain the biology of CLL, its diagnosis, treatment options, and long-term management strategies. This empowers patients and care partners to better understand the disease and its challenges, and to participate actively in treatment decisions.
Immunity & Infection Management
With a focus on the immune dysfunction that is central to CLL, ECLLA prioritises research and education on immunity and infection management. This includes establishing a dedicated working group and developing Europe-wide guidelines on vaccination and infection prevention for people living with CLL.
Research & Data Collaboration
ECLLA aims to establish a comprehensive European CLL Registry to collect anonymised data on treatment outcomes and immune-related complications. This collaborative effort will enhance research capabilities and promote standardised protocols across Europe.
Identified unmet needs
Across Europe, people living with CLL experience significant inequalities. ECLLA’s mission is to reduce these disparities by strengthening European collaboration, evidence-based advocacy, and shared learning to ensure equitable, high-quality CLL care regardless of geography.
ECLLA MEMBERSHIP
Full
Associate
Affiliated
Professional
Professional Members is intended for individual clinicians, researchers, and policy professionals.
We would like to thank the following ECLLA foundational funders for their support:
